[go: up one dir, main page]

SG11201810853UA - Anti-tnfrsf25 antibodies - Google Patents

Anti-tnfrsf25 antibodies

Info

Publication number
SG11201810853UA
SG11201810853UA SG11201810853UA SG11201810853UA SG11201810853UA SG 11201810853U A SG11201810853U A SG 11201810853UA SG 11201810853U A SG11201810853U A SG 11201810853UA SG 11201810853U A SG11201810853U A SG 11201810853UA SG 11201810853U A SG11201810853U A SG 11201810853UA
Authority
SG
Singapore
Prior art keywords
international
antibodies
pct
durham
english
Prior art date
Application number
SG11201810853UA
Other languages
English (en)
Inventor
Taylor H Schreiber
Jeff T Hutchins
Original Assignee
Pelican Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pelican Therapeutics Inc filed Critical Pelican Therapeutics Inc
Publication of SG11201810853UA publication Critical patent/SG11201810853UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201810853UA 2016-06-09 2017-06-09 Anti-tnfrsf25 antibodies SG11201810853UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662348009P 2016-06-09 2016-06-09
PCT/US2017/036817 WO2017214547A1 (en) 2016-06-09 2017-06-09 Anti-tnfrsf25 antibodies

Publications (1)

Publication Number Publication Date
SG11201810853UA true SG11201810853UA (en) 2019-01-30

Family

ID=59078259

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810853UA SG11201810853UA (en) 2016-06-09 2017-06-09 Anti-tnfrsf25 antibodies

Country Status (15)

Country Link
US (3) US10005843B2 (he)
EP (1) EP3468998B1 (he)
JP (1) JP6961625B2 (he)
KR (1) KR102423942B1 (he)
CN (1) CN109219620B (he)
AU (1) AU2017278192A1 (he)
BR (1) BR112018075222A2 (he)
CA (1) CA3026652A1 (he)
DK (1) DK3468998T3 (he)
IL (1) IL263406B2 (he)
MX (1) MX389320B (he)
RU (1) RU2746314C2 (he)
SG (1) SG11201810853UA (he)
WO (1) WO2017214547A1 (he)
ZA (1) ZA201808317B (he)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201705844SA (en) * 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US20220298252A1 (en) * 2019-08-30 2022-09-22 Pelican Therapeutics, Inc. Methods of treating cancer using tnfrsf25 antibodies
WO2022212668A1 (en) * 2021-03-31 2022-10-06 Heat Biologics, Inc. Methods and compositions related to tnfrsf25/dr3 agonists
CN116514983A (zh) * 2023-06-02 2023-08-01 安徽金百奥生物科技有限公司 一种靶向dr3胞外域的纳米抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE247168T1 (de) 1991-03-06 2003-08-15 Merck Patent Gmbh Humanisierte monoklonale antikörper
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
US5863537A (en) 1992-02-19 1999-01-26 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US20080233119A2 (en) 2003-08-20 2008-09-25 University Of Miami Compositions and methods for treating inflammatory lung disease
US7612179B2 (en) 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
JP5164167B2 (ja) 2005-08-30 2013-03-13 ユニバーシティー オブ マイアミ 免疫調節性腫瘍壊死因子受容体２５（ｔｎｆｒ２５）のアゴニスト、アンタゴニスト及び免疫毒素
SG178712A1 (en) 2006-10-02 2012-03-29 Medarex Inc Human antibodies that bind cxcr4 and uses thereof
FR2907341B1 (fr) 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
ES2586837T3 (es) * 2009-08-03 2016-10-19 University Of Miami Método para la expansión in vivo de linfocitos T reguladores
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
JP2016504045A (ja) 2013-01-09 2016-02-12 ザ ユニバーシティー オブ マイアミＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ ＴＬ１Ａ−Ｉｇ融合タンパク質を用いる制御性Ｔ細胞の制御のための組成物及び方法
RU2551235C2 (ru) * 2013-08-26 2015-05-20 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1
CN103592439B (zh) * 2013-09-03 2015-10-21 天津亿美诺生物科技有限公司 人尿路上皮癌特异性抗体及其应用
US9982057B2 (en) 2014-11-17 2018-05-29 Pelican Therapeutics, Inc. Human TNFRSF25 antibody

Also Published As

Publication number Publication date
US20170355773A1 (en) 2017-12-14
US10005843B2 (en) 2018-06-26
IL263406A (he) 2018-12-31
JP6961625B2 (ja) 2021-11-10
CA3026652A1 (en) 2017-12-14
RU2018143977A (ru) 2020-07-09
US10683359B2 (en) 2020-06-16
WO2017214547A1 (en) 2017-12-14
KR102423942B1 (ko) 2022-07-22
IL263406B1 (he) 2023-05-01
AU2017278192A1 (en) 2018-12-13
US20180312599A1 (en) 2018-11-01
CN109219620B (zh) 2023-01-31
RU2746314C2 (ru) 2021-04-12
KR20190015716A (ko) 2019-02-14
MX2018014716A (es) 2019-03-11
US20210017287A1 (en) 2021-01-21
MX389320B (es) 2025-03-20
BR112018075222A2 (pt) 2019-03-19
CN109219620A (zh) 2019-01-15
IL263406B2 (he) 2023-09-01
EP3468998B1 (en) 2021-12-01
ZA201808317B (en) 2019-08-28
RU2018143977A3 (he) 2020-10-05
JP2019526528A (ja) 2019-09-19
DK3468998T3 (en) 2022-03-07
EP3468998A1 (en) 2019-04-17

Similar Documents

Publication Publication Date Title
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811432WA (en) Rna for cancer therapy
SG11201808196UA (en) Neoantigens and methods of their use
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201810853UA (en) Anti-tnfrsf25 antibodies
SG11201408261UA (en) Syringe
SG11201907196YA (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same
SG11201909495PA (en) Combination cancer immunotherapy with pentaaza macrocyclic ring complex
SG11201808829VA (en) Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease